Drug intelligence / Profile preview

RB014

Development stage: Preclinical
Lead developer: Rose Biosciences
Modality: Small Molecules
Administration: Oral

Overview

**RB014** is an orally administered small molecule discovered by Rose Biosciences, originating from bacterial communities in the human body, that influences host metabolism to promote weight loss. Pre-clinical studies demonstrate **16-20% weight loss** in animal models with no anticipated side effects or safety concerns, surpassing current therapies (8-16% weight loss) in efficacy while being easier to manufacture. Developed from research at the Medical College of Wisconsin, it targets the obesity pandemic, with the company securing pre-seed funding in 2022 for further IP and licensing.[1][3][11]

Beyond the preview

Go deeper on RB014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RB014.

Explore the full profile